Imatinib mesylate (IM, Glivec®) and the 2 nd generation tyrosine kinase inhibitors (TKIs) (dasatinib and nilotinib) are the standard treatment for children and adults with chronic myeloid leukemia (CML). IM inhibits all ABL tyrosine kinases and selectively suppresses the ATP-binding site of
No takes yet. Share an insight, caveat, or question.
Giona et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: